Patents Assigned to National Jewish Medical and Research Center
-
Publication number: 20060223769Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.Type: ApplicationFiled: December 27, 2005Publication date: October 5, 2006Applicant: National Jewish Medical and Research CenterInventors: Steven Dow, Robyn Elmslie, Jurgen Karl Schwarze, Erwin Gelfand
-
Patent number: 7090865Abstract: Disclosed are a composition and method to treat or prevent antibody-induced anemia and particularly, autoimmune hemolytic anemia. The composition comprises a bisphosphonate and a pharmaceutically acceptable carrier. In a preferred embodiment, the composition comprises clodronate and a liposome carrier.Type: GrantFiled: November 27, 2002Date of Patent: August 15, 2006Assignee: National Jewish Medical and Research CenterInventors: Michael Jordan, Philippa Marrack, John Kappler
-
Publication number: 20060135585Abstract: Methods for therapy of cystic fibrosis and other conditions such as cancer are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis, cancer and/or another condition responsive to stimulation of thiol-containing compound transport.Type: ApplicationFiled: November 15, 2005Publication date: June 22, 2006Applicant: National Jewish Medical and Research CenterInventors: Brian Day, Remy Kachadourian
-
Publication number: 20060111315Abstract: Disclosed is a method for inhibiting the growth of a microorganism by high efficiency transfection of a human host cell with a nucleic acid encoding an antimicrobial agent, such that the host cell expresses the antimicrobial agent effective to inhibit growth of the microorganism.Type: ApplicationFiled: June 9, 2005Publication date: May 25, 2006Applicants: University of Medicine and Dentistry of New Jersey, National Jewish Medical and Research CenterInventors: Kevin Kisich, Gill Diamond
-
Publication number: 20060094054Abstract: Disclosed is a method and test kit to diagnose tumorigenicity or the presence of tumor cells in a patient by detecting the level of FBLN-3 expression or biological activity in the patient. Also disclosed are methods to identify regulators of tumor cell growth, motility and/or invasion, by identifying regulators of FBLN-3 expression or activity. Methods to identify anti-angiogenic and pro-angiogenic agents are also described, wherein such factors regulate the expression and/or activity of FBLN-3. Finally, the present invention relates to therapeutic methods and reagents for the inhibition of tumor growth and development and/or for the inhibition or promotion of angiogenesis, using FBLN-3, homologues and analogs thereof, and agents that modulate the expression and/or activity of FBLN-3.Type: ApplicationFiled: November 4, 2005Publication date: May 4, 2006Applicant: National Jewish Medical and Research CenterInventors: William Schiemann, Allan Albig
-
Publication number: 20060074062Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: ApplicationFiled: May 12, 2005Publication date: April 6, 2006Applicants: DUKE UNIVERSITY, NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Irwin Fridovich, Ines Batinic-Haberle, James Crapo, Brian Day
-
Publication number: 20060058245Abstract: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of thiol-containing compound transport.Type: ApplicationFiled: August 24, 2005Publication date: March 16, 2006Applicant: National Jewish Medical and Research CenterInventors: Brian Day, Richard Sawyer, Lee Newman
-
Publication number: 20060030539Abstract: Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and/or anti-mucin compounds, as well as other therapeutic compounds and compositions.Type: ApplicationFiled: August 4, 2005Publication date: February 9, 2006Applicant: National Jewish Medical and Research CenterInventors: Jerry Nick, Travis Walker, G. Worthen
-
Publication number: 20050260198Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.Type: ApplicationFiled: February 10, 2005Publication date: November 24, 2005Applicants: The Regents of the University of Colorado, National Jewish Medical and Research Center, MUSC Foundation for Research DevelopmentInventors: Vernon Holers, Joshua Thurman, Christian Taube, Erwin Gelfand, Gary Gilkeson
-
Publication number: 20050260140Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. Also disclosed are compositions and methods for inhibiting elastase in a patient. The compositions contains a compound containing a dithiol active-site in reduced state and optionally further contains a reducing system.Type: ApplicationFiled: March 24, 2005Publication date: November 24, 2005Applicants: National Jewish Medical and Research Center, The United States Government as Represented by the Secretary of the NavyInventors: Carl White, Greg Del Val, Rees Lee
-
Patent number: 6951733Abstract: A novel agar medium for the isolation, sub-cultivation, and indirect or direct drug-susceptibility testing of Mycobacterium tuberculosis is disclosed. Also disclosed are methods of isolating and growing Mycobacterium tuberculosis and methods of drug-resistance screening using the agar medium of the invention.Type: GrantFiled: June 16, 2003Date of Patent: October 4, 2005Assignee: National Jewish Medical and Research CenterInventors: Leonid Heifets, Tracy Sanchez
-
Patent number: 6916799Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: GrantFiled: June 14, 2001Date of Patent: July 12, 2005Assignees: Duke University, National Jewish Medical and Research CenterInventors: Irwin Fridovich, Ines Batinic-Haberle, James D. Crapo, Brian J. Day
-
Patent number: 6875749Abstract: A method of facilitating vascular growth in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to stimulate vascular growth in the subject (e.g., in the lungs or heart of the subject). Pharmaceutical formulations useful for carrying out such methods (e.g., an antibody that specifically binds to EMAP II in a pharmaceutically acceptable carrier) and screening techniques useful for identifying additional compounds that can be used for carrying out such methods are also disclosed.Type: GrantFiled: August 13, 2001Date of Patent: April 5, 2005Assignees: Childrens Hospital Los Angeles, National Jewish Medical and Research CenterInventors: Margaret A. Schwarz, Fangrong Zhang, Sarah A. Gebb
-
Publication number: 20050048055Abstract: The invention relates to methods for altering and enhancing the immune response toward an antigen. More specifically, the present invention relates to methods of using CD40 engagement on T cells to induce T cell receptor gene rearrangement and enhance T cell affinity for a particular antigen. The invention also relates to methods for promoting developmental maturation of an immature cell of the T cell lineage.Type: ApplicationFiled: September 13, 2004Publication date: March 3, 2005Applicants: University of Vermont and State Agricultural College, National Jewish Medical and Research CenterInventors: Martha Newell, Evan Newell, David Wagner
-
Publication number: 20040181037Abstract: Disclosed are phosphatidylserine (PS) receptors, including PS receptors from human, mouse, Drosophila melanogaster and Caenorhabditis elegans. Also disclosed are homologues of such receptors, nucleic acids encoding such receptors and homologues thereof, as well as agonist and antagonist compounds that specifically associate with and affect the activation state of such receptors. Preferred agonists and antagonists of PS receptors according to the invention include antibodies, antibody fragments and binding partners that selectively bind to such a receptor. Also disclosed are methods of making and using the PS receptors, homologues thereof, and agonist and antagonist compounds of such receptors. In particular, methods for reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, methods of increasing anti-tumor immunity, and methods for inhibiting viral and parasitic infections are described.Type: ApplicationFiled: July 22, 2003Publication date: September 16, 2004Applicant: National Jewish Medical and Research CenterInventors: Valerie A. Fadok, Peter M. Henson
-
Publication number: 20040097454Abstract: Described is a method for modulating the phenotype of a cell, and particularly, of a target cell in a patient who has or is at risk of developing a disease or condition in which is associated with dysregulation of cellular phenotype. The method includes administration of a recombinant nucleic acid molecule encoding a protein having CREB biological activity or dominant negative CREB biological activity to a patient, in such a manner that the protein is expressed in a target cell of a patient and is sufficient to modulate the phenotype of the target cell. Such a method is particularly useful in patients who have, or at risk of developing, diabetes, obesity, macrovascular disease, heart failure, osteoarthritis, and neural diseases and conditions.Type: ApplicationFiled: May 6, 2003Publication date: May 20, 2004Applicants: University Technology Corporation, National Jewish Medical and Research Center, U.S. Government as represented by the Department of Veterans AffairsInventors: Jane E. Reusch, Dwight J. Klemm
-
Patent number: 6737398Abstract: Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of &ggr;&dgr; T cells in a patient. Also disclosed are methods for identifying compounds hyperresponsiveness by modulating &ggr;&dgr; T cell action.Type: GrantFiled: September 28, 2000Date of Patent: May 18, 2004Assignee: National Jewish Medical and Research CenterInventors: Erwin Gelfand, Willi K. Born, Michael F. Lahn, Arihiko Kanehiro
-
Publication number: 20040039211Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: ApplicationFiled: April 28, 2003Publication date: February 26, 2004Applicant: DUKE UNIVERSITY AND NATIONAL JEWISH MEDICAL AND RESEARCH CENTERInventors: Irwin Fridovich, Ines Batinic-Haberle, Ivan Spasojevic, James D. Crapo, Brian J. Day
-
Patent number: 6693086Abstract: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.Type: GrantFiled: June 25, 1998Date of Patent: February 17, 2004Assignee: National Jewish Medical and Research CenterInventors: Steven W. Dow, Robyn E. Elmslie, Jürgen Karl Johannes Schwarze
-
Publication number: 20040023941Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: ApplicationFiled: January 23, 2003Publication date: February 5, 2004Applicants: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER, AEOLUS PHARMACEUTICALS, INC., DUKE UNIVERSITYInventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle